Showing 2361-2370 of 8833 results for "".
Nail Disease and JAK Inhibitor Safety
https://practicaldermatology.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Study Examines Socioeconomic Status and HS Diagnosis
https://practicaldermatology.com/series/dermwire-tv/study-examines-socioeconomic-status-and-hs-diagnosis/35859/In this week's DermwireTV, a new study examines the association between socioeconomic status and HS diagnosis; a new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo; and in our “Updates on Skin Cancer” feature, we hear about how to use gene expression profile testing fSunscreen as Self-Care
https://practicaldermatology.com/series/c-suite-chats/sunscreen-as-self-care/33249/Arielle Moody, product developer at Mama Sol, talks about the importance of sunscreen in beauty routines and how her company is attempting to make it more appealing.DermWire TV Extra: Spironolactone on TikTok
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-spironolactone-on-tiktok/33016/George Washington University clinical instructor of Dermatology Emily Murphy, MD, and medical student Savanna Vidal discuss their research regarding the quality and reliability of information on TikTok about spironolactone for acne treatment.Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.Dr. Eichenfield Urges Caution for Steroid-Phobia at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-eichenfield-urges-caution-for-steroid-phobia-at-maui-derm/32919/In addition to the various clinical skin conditions that pediatric patients present with, dermatologists now must understand how to deal with steroid-phobia, according to Lawrence Eichenfield, MD.Various Skin Cancer Therapies Covered at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/various-skin-cancer-therapies-covered-at-maui-derm/32915/With a theme of understanding the various options available for treatment of skin cancers and selecting the correct ones for each case, George Martin, MD, Ted Rosen, MD, and Emily Ruiz, MD, MPH, presented “Cutaneous Oncology Update 2025” at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.Leading Dermatologists Summarize Maui Derm Presentations
https://practicaldermatology.com/series/dermwire-tv/leading-dermatologists-summarize-maui-derm-presentations/32839/In this week's DermwireTV, top thought leaders provide a summary of their presentations at Maui Derm; a new analysis examines a link between hidradenitis suppurativa genetics and coronary artery disease risk; and the president of Castle Biosciences joins us for this week's C-Suite Chats fJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseCanadian Perspective: Drs. Bhatia, Sapijaszko, and Kaufmann
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/canadian-perspective-drs-bhatia-sapijaszko-and-kaufmann/32695/Neal Bhatia, MD, speaks with Canadian Dermatology Association vice president Mariusz Sapijaszko, MD, FAACS, and former American Academy of Dermatology president Mark Kaufmann, MD, about different perspectives on advocacy in dermatology, including the use of patient stories.